Abstract: Provided are antibodies or fragment thereof having binding specificity to the human solute carrier 34 A2 (SLC34A2) protein. These antibodies are capable of binding to SLC34A2 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC) and effectively induce endocytosis. Also provided are methods and uses for treating cancers.

Abstract: Provided are bispecific antibodies capable of binding to human VEGF protein and human PD-1 protein. These bispecific antibodies are effective in treating cancer.

Abstract: Provided are antibodies and fragments thereof having binding specificity to the liver receptor homolog 1 (LIV-1. SLC39A6 or ZIP6) protein as well as their derivatives and uses.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein and also capable of binding the M149L mutant. By contrast, such antibodies and fragments do not or weakly bind to claudin 18.1 (CLDN18.1).

Abstract: Provided are antibodies and fragments thereof having binding specificity to the claudin 6 (CLDN6) protein as well as their derivatives and uses.

Abstract: Provided are anti-AMHRII antibodies and antigen-binding fragments, as well as their bispecific or multispecific counterparts. Methods of using the antibodies for treating and diagnosing diseases such as cancer are also provided.

Abstract: Provided are anti-4-1BB nanobodies and bispecific or multispecific antibodies that incorporate the nanobodies. Methods of using the antibodies for treating and diagnosing diseases such as cancer are also provided.

Abstract: Provided are antibodies and fragments thereof having binding specificity to the liver receptor homolog 1 (LIV-1, SLC39A6 or ZIP6) protein as well as their derivatives and uses.

Abstract: Provided are antibodies and fragments thereof having binding specificity to the claudin 6 (CLDN6) protein as well as their derivatives and uses.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human solute carrier 34 A2 (SLC34A2) protein. These antibodies are capable of binding to SLC34A2 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC) and effectively induce endocytosis. Also provided are methods and uses for treating cancers.

Abstract: Provided are bispecific or multispecific antibodies that include an anti-CEACAM5 portion and one or more anti-4-1BB nanobodies whose agonist activity is dependent on the presence of the CEACAM5 antigen. Such bispecific or multispecific antibodies are safe, and are efficacious in treating cancer and have long-term protective immunological memory against tumors. Methods of using the antibodies for treating diseases such as cancer are also provided.

Abstract: The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein and also capable of binding the M149L mutant. By contrast, such antibodies and fragments do not or weakly bind to claudin 18.1 (CLDN18.1).

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C-C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).

Abstract: Provided are antibodies and fragments having binding specificity to the signal regulatory protein alpha (SIRP?) protein and to the programmed death-ligand 1 (PD-L1) protein. The antibodies and fragments can bring peripheral macrophages to PD-L1+ tumor site, thereby enhancing tumor treatment.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C—C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).

Abstract: Provided are antibody-drug conjugates containing a drug moiety attached to an antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the ?3-?4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the ?5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.

Abstract: Provided are chimeric antigen receptors that include an antibody or fragment thereof having binding specificity to the human GPRC5D protein. The chimeric antigen receptors and immune cells expressing the chimeric antigen receptors are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.

Abstract: Wire arc additive manufacturing-spinning combined machining device and method are provided. The machining device includes a spinning mechanism and a fused deposition modeling mechanism. The spinning mechanism includes a machine tool and a spinning head. The spinning head is installed on the machine tool by a main shaft, and the main shaft is configured to drive the spinning head to rotate to achieve the movement in three vertical directions. The spinning head includes a spinning base and balls. Each of the balls is installed in a corresponding one of arc grooves at a bottom of the spinning base. The fused deposition modeling mechanism includes a moving track, a robot and a heat source generator. The arc moving track is arranged around the machine tool in a surrounding mode. The robot is movably installed on the moving track. The heat source generator is installed at a tail end of the robot.

Abstract: Provided are antibody-drug conjugates containing a drug moiety attached to an antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the ?3-?4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the ?5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.